Higher response to @entity6985 in relapsed/refractory XXXX in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.

@entity1 @entity1892 @entity6985
BACKGROUND: There is a need to develop novel therapies for relapsed/refractory @entity1892 ( @entity1892 ) and to identify biomarkers predictive for therapeutic response. @entity6985 was previously shown to induce an overall response rate (ORR) of 28% in @entity1 with relapsed/refractory @entity1892 . It is currently unknown if response rates differ between @entity1 with different @entity1892 subtypes. METHODS: The authors retrospectively evaluated clinical outcomes of @entity1 with germinal center B-cell-like versus nongerminal center B-cell-like @entity1892 treated with salvage @entity6985 at 4 academic institutions. RESULTS: Forty @entity1 with relapsed/refractory @entity1892 were included (24 @entity1 ; 16 @entity1 ; median age, 66 years; median of 4 prior treatments, including rituximab chemotherapy). @entity1 were classified as germinal center B-cell-like (n = 23) or nongerminal center B-cell-like (n = 17) @entity1892 according to the Hans algorithm. The subgroups were similar in terms of stage, international prognostic index score, prior number of treatments, and rituximab resistance. A significant difference in clinical response to @entity6985 was observed in nongerminal center B-cell-like versus germinal center B-cell-like @entity1 . ORR was 52.9% versus 8.7% (P = .006); complete response rate was 23.5% versus 4.3%. Median progression-free survival was 6.2 versus 1.7 months (P = .004), although no difference in OS was observed between nongerminal center B-cell-like and germinal center B-cell-like @entity1892 @entity1 . CONCLUSIONS: The data suggest that the 2 major subgroups of @entity1 with @entity1892 (germinal center B cell and nongerminal center B cell) have different antitumor responsiveness to @entity6985 in the relapsed/refractory setting. A large international trial (NCT01197560) has been opened to enrollment in an attempt to prospectively validate these retrospective observations.
